New York, Feb 2, 2026, 12:13 EST — Regular session
- JNJ shares up about 0.8% midday, tracking modest gains in U.S. stocks
- Company flagged new real-world data backing Erleada in advanced prostate cancer
- Investors look for follow-through from doctors and payers, plus the next key dates on the calendar
Johnson & Johnson shares rose on Monday after the company released fresh data on its prostate cancer drug Erleada, adding to a steady bid for large healthcare names in a firm U.S. market.
The stock was up $1.84, or about 0.8%, at $229.09 in midday trade.
The update matters because drug makers are leaning harder on evidence that can shift prescribing in crowded categories. Investors have also been quick to reward companies that can defend growth as pricing scrutiny and competition bite across parts of U.S. healthcare.
Erleada competes in a market where small differences in outcomes can steer treatment choices. Head-to-head comparisons are rare, and they can influence not only doctors but also insurers that decide which drugs get preferred coverage.
Johnson & Johnson said a retrospective “real-world” study — analysis drawn from routine clinical practice records — showed patients with metastatic castration-sensitive prostate cancer had a 51% lower risk of death over 24 months when treated with Erleada without docetaxel versus darolutamide without docetaxel. A hazard ratio below 1.0 indicates a lower event risk in the Erleada group, the company said. PR Newswire
“These real-world data show the survival benefit of apalutamide versus darolutamide,” said Mehmet Bilen, director of the Genitourinary Medical Oncology Program at Winship Cancer Institute of Emory University. Mahadi Baig, vice president of U.S. medical affairs at Johnson & Johnson Innovative Medicine, said “real-world comparisons can provide critical information to support patient care” when run with rigorous methods. JNJ.com
Darolutamide is sold as Nubeqa and was developed jointly by Bayer and Orion Corporation, according to the company. bayer.com
Johnson & Johnson touched an intraday high of $231.14 and a low of $227.56. The move roughly matched gains in the broader market and the health-care sector, keeping the reaction contained to the data release rather than any wider rerating.
The company last disclosed its quarterly results in a filing dated Jan. 21. SEC
Still, real-world studies can cut both ways. Because they are not randomized trials, outcomes can be skewed by differences in the kinds of patients who receive each drug, and rivals can push back on methodology. Johnson & Johnson also carries a long-running litigation overhang tied to its discontinued talc products, which investors continue to price as a tail risk.
Next, investors will watch for any read-through as the Erleada findings are discussed at the Prostate Cancer Update, and for Feb. 24, when the stock is due to go ex-dividend ahead of a March 10 payout. JNJ.com
